Clinical Trial Update: Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating efficacy and safety of ruxolitinib in Chinese participants with corticosteroid-refractory chronic graft-versus-host dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graft vs. Host Disease, Chronic Graft vs. Host Disease | Phase 4 | Status: RECRUITING